When coalitions are absent: Effect sizes for categorization by race (Study 1) and gender (Study 2). by David Pietraszewski (521525)

a: SPM images of brain dopamine changes. by Gene-Jack Wang (245944)

LFP model. by M. Sohail Noor (17457645)

The β2AR Pathway Involves PI3K/AKT in Controlling Keratinocyte Migration by Raja K Sivamani (587219)

“…Error bars represent standard error of the mean, <i>n =</i> 4; <i>* p <</i> 0.05.</p> <p>(B) Keratinocyte migration was measured after exposure to either procaterol (10 nM), ICI-118,551 (20 μM, specific β2AR antagonist), procaterol with ICI-118,551, LY294002 (50 μM, PI3K inhibitor), or LY294002 (50 μM) with ICI-118,551 (20 μM). …”

Characterization of purified esAEVs based on protein content and the localization of Mif on the surface. by Safia A. Essien (20108379)

Familiarization enlarges the differences between familiar- and novel-odor representations in AL. by Hong Lei (53686)

P-α-syn expression in the appendix/cecum across species. by Alexandra D. Zinnen (8259906)

Insulin Resistance in Relation to Lipids and Inflammation in Type-2 Diabetic Patients and Non-Diabetic People by Ying-Mei Feng (2609680)

“…</p><p>Methods</p><p>We studied 798 Chinese patients with type-2 diabetes (53.6% women; mean age, 60.6 years) admitted to a tertiary referral centre and 1060 white Flemish (50.5%; 51.1 years) randomly recruited in Northern Belgium. …”

Fano factor of single neurons and of populations. by Tomas Barta (8067509)

“…<p><b>A-C</b>: Mean Fano factor of individual neurons for different values of <i>P</i>_ext: 0.01 (<b>A</b>), 0.2 (<b>B</b>), 1 (<b>C</b>). …”

Domperidone treatment reduces cystic growth in <i>Pkd1</i>^{<i>–/–</i>}mice. by Parama Paul (6667835)

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”

Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. …”